CriticalErgot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist×Systemic antimycotics. Imidazole derivatives
Updated · Methodology
Mechanism
Ketoconazole is a strong inhibitor of the liver enzyme CYP3A4 and can raise the levels of drugs that this enzyme metabolises (ketoconazole summary of product characteristics, SmPC, European Medicines Agency, EMA; ketoconazole labels, US Food and Drug Administration, FDA). According to the ketoconazole documents, levels of ergot alkaloids, including dihydroergotamine, may rise with ketoconazole, and with them the risk of ergotism, a vasospasm that can lead to ischaemia of the brain and limbs (EMA, FDA). According to the US dihydroergotamine labels, CYP3A4 inhibition likewise raises dihydroergotamine blood levels and the risk of such vasospasm (dihydroergotamine labels, FDA). With the strong inhibitor itraconazole, exposure to dihydroergotamine itself rose by 14–19%, while exposure to its main active metabolite, an equally potent venoconstrictor, rose about 3- to 4-fold (dihydroergotamine label, FDA). The documents report no study of dihydroergotamine with ketoconazole. The EU ketoconazole SmPC notes that the size of its interactions may depend on the dose: a stronger effect can be expected at a higher dose or a shorter dosing interval (EMA).
Symptoms
With excess dihydroergotamine, the muscles ache, the fingers and toes become numb, cold, pale or bluish, and pulses in the arms and legs weaken or disappear (dihydroergotamine labels, US Food and Drug Administration, FDA). Leg ischaemia causes cramping and pain in the legs or hips, heaviness or tightness in the leg muscles, burning or aching pain in the feet or toes at rest, and coldness or colour change in one or both legs. Brain ischaemia causes slurred speech and sudden weakness (dihydroergotamine labels, FDA). Myocardial and colonic ischaemia have also been reported. Severe poisoning causes nausea, vomiting, abdominal pain, respiratory depression, a rise and then usually a fall in blood pressure, confusion, delirium, seizures and coma (dihydroergotamine labels, FDA). Persistent vasospasm in people with poor circulation can lead to gangrene or death (dihydroergotamine labels, FDA).
Management
The combination is contraindicated. The EU and US ketoconazole documents list dihydroergotamine among the contraindicated ergot alkaloids (ketoconazole summary of product characteristics, SmPC, European Medicines Agency, EMA; ketoconazole labels, US Food and Drug Administration, FDA). The dihydroergotamine labels contraindicate strong CYP3A4 inhibitors and name ketoconazole among them (dihydroergotamine labels, FDA). Dihydroergotamine is not in the Spanish medicines register. Under the US ketoconazole labels, do not give contraindicated drugs during ketoconazole treatment or for up to one week after it is stopped (ketoconazole labels, FDA). The contraindication concerns oral ketoconazole: in the European Union, ketoconazole tablets are used for endogenous Cushing's syndrome, and doctors experienced in endocrinology or internal medicine start and supervise the treatment (EMA). Ketoconazole cream on adult skin and gel on the scalp gave no measurable plasma levels, but gel applied to the whole body did. No interaction studies have been done with the cream or gel (ketoconazole cream and gel SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Tell the patient to stop dihydroergotamine and get emergency help at once if they develop cramping and pain in the legs, numbness, coldness or colour change in the legs, slurred speech or sudden weakness (dihydroergotamine labels, FDA). In overdose, stop dihydroergotamine, support and monitor vital functions, and observe the patient for at least 24 hours or for as long as symptoms persist. Warm the affected area, give vasodilators and provide nursing care to prevent tissue damage (dihydroergotamine labels, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ketoconazole tablets (ketoconazole) prescribing information (2025)– FDA, DailyMed setid 6d4be760-c723-4f54-a854-12c61cf91703 (Strides Pharma Science Limited), version 8, revised 12/2025, Boxed Warning, Contraindications, Warnings (incl. QT Prolongation), Precautions: Drug Interactions, Medication Guide
- FDA: Ketoconazole Tablets USP 200 mg prescribing information (2026)– FDA label, DailyMed setid 1d598696-c6f3-4b7c-ad73-949d2089df35, revised 08/2026, Contraindications
- FDA: ATZUMI (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid 0982a44a-dc0c-75c0-e063-6394a90a6d6c, revisión 06/2026 (versión 3), secciones 4, 5.5, 5.6 y 7.2
- FDA: TRUDHESA (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid b81397b0-910d-4eb4-8fee-a9a3c9d94d63, revisión 09/2026 (versión 7), secciones 4 y 7.2
- EMA: Ficha técnica: Ketoconazol (EU/1/14/965), sección 4.3 (2025)– EMA, Ketoconazole Esteve 200 mg comprimidos (autorización europea por procedimiento centralizado), EU/1/14/965/001, ficha técnica (anexo I), información del producto actualizada el 05.05.2025, secciones 4.1, 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Fungarest 20 mg/g crema (ketoconazol) (nº registro 57595), sección 5.2 (2023)– AEMPS, CIMA, nº registro 57595 (Fungarest 20 mg/g crema, Stada), documento 04/2023 (texto revisado 06/2021), secciones 4.5 y 5.2 (sin concentraciones plasmáticas cuantificables tras uso en la piel de adultos)
- AEMPS: Ficha técnica: Ketoconazol Sandoz 20 mg/g gel (nº registro 66037), sección 5.2 (2023)– AEMPS, CIMA, nº registro 66037 (Sandoz), documento 11/2023 (texto revisado 12/2021), secciones 4.5 y 5.2 (niveles plasmáticos detectados tras aplicación en todo el cuerpo)
- FDA: Dihydroergotamine mesylate nasal spray, Cipla (dihydroergotamine) prescribing information (2025)– FDA, DailyMed setid 1ecb2311-eee3-4230-a019-a3496308cff1 (Cipla USA), versión 10 (SPL 29.12.2025, texto revisado 05/2022), Contraindications